Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.
Manohar
Vinayak A
VA
Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Moder
Kevin G
KG
Edwards
William D
WD
Klarich
Kylew
K
D018501:Antirheumatic Agents / Q000009:adverse effects; D002313:Cardiomyopathy, Restrictive / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology*; D004452:Echocardiography; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D017379:Hypertrophy, Left Ventricular / Q000139:chemically induced / Q000473:pathology; D007049:Iatrogenic Disease / Q000517:prevention & control; D002479:Inclusion Bodies / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D046529:Microscopy, Electron, Transmission; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology* / Q000648:ultrastructure; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000473:pathology
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine